Leanne McCabe

1 week ago | thelancet.com | Graham Cooke |Viet Nam |Barnaby Flower |Leanne McCabe

Introduction The development of direct-acting antivirals for hepatitis C virus (HCV) infection has transformed individual treatment and underpins ambitious WHO targets for global elimination of viral hepatitis as a public health threat by 2030.1 Of three WHO-recommended pan-genotypic first-line treatment options, two are preferred by lower-income and lower-middle-income countries and are available from generic manufacturers: sofosbuvir–daclatasvir and sofosbuvir–velpatasvir.2 No randomised...